<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2202-3-19.anc" start="17097" end="17101" sStart="-1" offset="0" sid="null" wn="4" wnkey="work%1:09:00::" text="This ligand had been described as a mixed agonist-antagonist opioid ligand [ 30 31 ] with agonistic activity at ? opioid receptors [ 32 ] . Overall very little &lt;b&gt;work&lt;/b&gt; has been done on xorphanol and little is &lt;b&gt;known&lt;/b&gt; about it except that it is an orally active analgesic with limited physical dependence liability [ 30 ] . Thus the present report describing its activity at ? opioid receptors provides useful data on this ligand." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2202-3-19.anc" start="17097" end="17101" sStart="null" offset="0" sid="null" wn="4" wnkey="work%1:09:00::" text="This ligand had been described as a mixed agonist-antagonist opioid ligand [ 30 31 ] with agonistic activity at ? opioid receptors [ 32 ] . Overall very little &lt;b&gt;work&lt;/b&gt; has been done on xorphanol and little is &lt;b&gt;known&lt;/b&gt; about it except that it is an orally active analgesic with limited physical dependence liability [ 30 ] . Thus the present report describing its activity at ? opioid receptors provides useful data on this ligand." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="15744" end="15748" sStart="null" offset="27" sid="r11.true.j.0119" wn="1" wnkey="true%3:00:00::" text="A different scenario holds true for the two ligands, xorphanol and WIN 44,441." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="14328" end="14337" sStart="null" offset="309" sid="null" wn="3" wnkey="suggest%2:32:02::" text="Muscular rigidity of fentanyl has been suggested to occur via several mechanism involving glutamatergic pathways [ 25 ] , serotonergic system [ 26 ] as well as noradrenergic system [ 27 28 ] . One other potential pathway may be via regulation of dopaminergic system as suggested before [ 29 ] possibly via ? opioid receptor system as explained here." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="8536" end="8546" sStart="null" offset="18" sid="r8.suggest.v.0873" wn="3" wnkey="suggest%2:32:02::" text="There is evidence suggesting that ? selective opioid ligands do not cause changes in respiratory parameters [ 13 ] . Thus, suggesting that designing specific ligands that act at ? opioid receptors may be useful in formulating analgesics without the side effect of ventilatory depression." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="14328" end="14337" sStart="null" offset="309" sid="null" wn="1" wnkey="suggest%2:32:00::" text="Muscular rigidity of fentanyl has been suggested to occur via several mechanism involving glutamatergic pathways [ 25 ] , serotonergic system [ 26 ] as well as noradrenergic system [ 27 28 ] . One other potential pathway may be via regulation of dopaminergic system as suggested before [ 29 ] possibly via ? opioid receptor system as explained here." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="14328" end="14337" sStart="null" offset="309" sid="null" wn="1" wnkey="suggest%2:32:00::" text="Muscular rigidity of fentanyl has been suggested to occur via several mechanism involving glutamatergic pathways [ 25 ] , serotonergic system [ 26 ] as well as noradrenergic system [ 27 28 ] . One other potential pathway may be via regulation of dopaminergic system as suggested before [ 29 ] possibly via ? opioid receptor system as explained here." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="14328" end="14337" sStart="null" offset="309" sid="null" wn="3" wnkey="suggest%2:32:02::" text="Muscular rigidity of fentanyl has been suggested to occur via several mechanism involving glutamatergic pathways [ 25 ] , serotonergic system [ 26 ] as well as noradrenergic system [ 27 28 ] . One other potential pathway may be via regulation of dopaminergic system as suggested before [ 29 ] possibly via ? opioid receptor system as explained here." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="7089" end="7094" sStart="null" offset="179" sid="r7.serve.v.0042" wn="1" wnkey="serve%2:42:03::" text="These cells do not express any endogenous ? opioid receptors, as they lack binding of the radioactive tracer [ 3H]-DPDPE (data not shown), thus they serve as a good system for the expression of opioid receptors." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="7089" end="7094" sStart="null" offset="179" sid="r7.serve.v.0042" wn="1" wnkey="serve%2:42:03::" text="These cells do not express any endogenous ? opioid receptors, as they lack binding of the radioactive tracer [ 3H]-DPDPE (data not shown), thus they serve as a good system for the expression of opioid receptors." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="7089" end="7094" sStart="null" offset="179" sid="r7.serve.v.0042" wn="1" wnkey="serve%2:42:03::" text="These cells do not express any endogenous ? opioid receptors, as they lack binding of the radioactive tracer [ 3H]-DPDPE (data not shown), thus they serve as a good system for the expression of opioid receptors." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="7089" end="7094" sStart="null" offset="179" sid="r7.serve.v.0042" wn="1" wnkey="serve%2:42:03::" text="These cells do not express any endogenous ? opioid receptors, as they lack binding of the radioactive tracer [ 3H]-DPDPE (data not shown), thus they serve as a good system for the expression of opioid receptors." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2202-3-19.anc" start="21978" end="21983" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="The assay was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration through Whatman GF/B filters using a FilterMate cell harvester (Packard Instruments) followed by three washes, 4 ml each, with ice cold buffer." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2202-3-19.anc" start="21978" end="21983" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="The assay was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration through Whatman GF/B filters using a FilterMate cell harvester (Packard Instruments) followed by three washes, 4 ml each, with ice cold buffer." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2202-3-19.anc" start="21978" end="21983" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="The assay was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration through Whatman GF/B filters using a FilterMate cell harvester (Packard Instruments) followed by three washes, 4 ml each, with ice cold buffer." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2202-3-19.anc" start="21978" end="21983" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="The assay was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration through Whatman GF/B filters using a FilterMate cell harvester (Packard Instruments) followed by three washes, 4 ml each, with ice cold buffer." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2202-3-19.anc" start="21978" end="21983" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="The assay was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration through Whatman GF/B filters using a FilterMate cell harvester (Packard Instruments) followed by three washes, 4 ml each, with ice cold buffer." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2202-3-19.anc" start="21978" end="21983" sStart="null" offset="0" sid="null" wn="2" wnkey="rapid%5:00:02:fast:01" text="The assay was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration through Whatman GF/B filters using a FilterMate cell harvester (Packard Instruments) followed by three washes, 4 ml each, with ice cold buffer." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="8042" end="8047" sStart="null" offset="58" sid="r1.order.n.0009" wn="4" wnkey="order%1:14:00::" text="The rank order of affinity agrees with the rank order of potency of these ligands in inhibiting forskolin-stimulated cAMP production." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="8042" end="8047" sStart="null" offset="58" sid="r1.order.n.0009" wn="4" wnkey="order%1:14:00::" text="The rank order of affinity agrees with the rank order of potency of these ligands in inhibiting forskolin-stimulated cAMP production." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="8042" end="8047" sStart="null" offset="58" sid="r1.order.n.0009" wn="4" wnkey="order%1:14:00::" text="The rank order of affinity agrees with the rank order of potency of these ligands in inhibiting forskolin-stimulated cAMP production." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="9948" end="9952" sStart="null" offset="30" sid="r10.help.v.0482" wn="3" wnkey="help%2:42:00::" text="Such information can not only help explain some of the paradoxical behavioural data of these ligands, but it can also explain the interaction of each ligand with a single receptor involved in modulation of the pain pathways." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="25348" end="25356" sStart="null" offset="266" sid="r11.function.n.0922" wn="2" wnkey="function%1:07:00::" text="Data from each experiment were normalized to the top of the curve (no ligand, 100%), expressed as percent inhibition of forskolin-stimulated cAMP accumulation and were fit to a sigmoidal function by using one site competition function as described below." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="518" end="526" sStart="null" offset="146" sid="r11.function.n.0466" wn="2" wnkey="function%1:07:00::" text="Delta opioid receptors play a modulatory role in analgesia, hibernation, autonomic nervous system function, neuroendocrine system function, mood driven behaviours and olfaction [ 2 ] . Thus, understanding the requirements for activation of ? opioid receptors can lead to identification and design of novel drugs acting through this receptor for treatment of various physiological problems." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="3720" end="3724" sStart="null" offset="201" sid="r9.full.j.0309" wn="2" wnkey="full%5:00:01:whole:00" text="The results obtained from this study will serve to define the relative efficacies and potencies of a set of opioid ligands compared to one another and differentiate between the full and partial agonists at ? opioid receptors." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="11882" end="11886" sStart="null" offset="153" sid="r9.full.j.0359" wn="3" wnkey="full%5:00:00:complete:00" text="Comparison of the efficacies of the set of agonists in this study to that of the endogenous ligand, met-enkephalin, showed that all were full agonists." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="15289" end="15293" sStart="null" offset="20" sid="r9.full.j.0306" wn="2" wnkey="full%5:00:01:whole:00" text="While fentanyl is a full agonist at ? opioid receptors, morphine is only a partial agonist." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="2515" end="2521" sStart="null" offset="367" sid="r10.common.j.0264" wn="3" wnkey="common%5:00:00:shared:00" text="Thus the present study was designed, (1) to describe the activation profiles of a set of opioid ligands not previously defined at an isolated cell system expressing only ? opioid receptors, and (2) to compare the relative efficacies and potencies of these ligands to the strongest ligand in the set, metazocine, to the common opioid analgesic, morphine and to the endogenous ? opioid ligand, met-enkephalin." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2202-3-19.anc" start="19424" end="19435" sStart="null" offset="15" sid="r11.combination.n.0206" wn="1" wnkey="combination%1:14:00::" text="(4) In combination with in vivo data characterizing analgesic and unwanted effects of these ligands, the in vitro data can be used to identify the activation profile of the ideal opioid analgesic that has minimal side effects." />
  </sentences>
</list>